Plain-English translation of NCT06389721 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is investigating how chemotherapy—specifically doxorubicin, cyclophosphamide, docetaxel, or paclitaxel—affects your brain and causes a side effect called peripheral neuropathy, which is nerve damage that causes pain, tingling, or numbness in your hands and feet. Researchers will track your brain activity using a test called an EEG and monitor your symptoms throughout your treatment. Some participants will also try a special brain-training program at home to see if it can help prevent or reduce nerve damage.
Nerve damage from chemotherapy is a common and serious side effect that can affect quality of life long after treatment ends, and doctors don't yet fully understand how it develops or how to prevent it. This study aims to fill that gap by looking at brain changes that happen during chemotherapy and testing whether a home-based brain-training tool can help protect you.
You likely qualify if…
You likely don't qualify if…
If you join, you will have a brain-activity scan (EEG) and complete a questionnaire before your chemotherapy starts. Then, depending on which group you're in, you'll either have monthly EEGs and questionnaires throughout your chemotherapy (up to 6 times total), or you'll do brain-training exercises twice a week at home for 2 weeks before chemotherapy starts and then twice a week during treatment (up to 32 sessions). The second group will also have EEGs and questionnaires before and after chemotherapy. All study visits at MD Anderson can be scheduled around your treatment appointments.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~45 participants
Started
July 2024
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lorenzo Cohen, PHD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.